Biomarkers Improve Odds Of Approval, BIO Study Finds
Executive Summary
BIO/Biomedtracker analysis strengthens the case for expanded use of drug development tools like biomarkers with finding that well-defined patient populations in clinical trials are associated with greater likelihood of approval.
You may also be interested in...
Myriad Builds Case For Personalized Prescribing Of Rheumatoid Arthritis Drugs
Data presented at the American College of Rheumatology meeting show that not everybody needs a biologic, and that biomarker testing could enable more cost-effective use, says Myriad subsidiary Crescendo.
Pharma R&D Productivity Shows Signs Of Progress
It now takes 13 drugs in Phase I to yield one marketed drug, compared to 19 in 2007 to 2011, according to new data from KMR Group.
Biomarkers Qualification: Can FDA Get Rolling Before A Push From Congress?
FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: